Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors

Journal of Medicinal Chemistry
T P MaduskuieP F Stouten

Abstract

The molecular modeling studies, rational design, and synthesis of a novel series of bisphenylamidine carboxylate compounds which are inhibitors of factor Xa in the blood coagulation cascade are described. Inhibition of blood coagulation has been proposed to have several potential therapeutic utilities (Kaiser and Hauptmann, Cardiovasc. Drug Rev. 1994, 12, 225-236). Factor Xa (fXa) holds a central position in the coagulation cascade (Coleman et al. in Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 1994, pp 3-18). Its major role is the generation of thrombin by the proteolytic cleavage of prothrombin. Inhibition of fXa would serve to reduce the formation of platelet clots. The fXa dimer crystal structure (Tulinsky et al., J. Mol. Biol. 1993, 232, 947-966) was used in our molecular modeling studies to design a novel series of fXa inhibitors. We initially docked and minimized isolated small molecule fragments in the S1 and S4 aryl-binding subsites. Subsequently, these fragments were connected with a tether, so as not to disturb the orientation of the fragments in their respective pockets. These modeling studies led to the initial compound (1) which was found to have significant inhibitory potency for fXa (Ki = 3...Continue Reading

Citations

Apr 3, 1999·Medicinal Research Reviews·P E Sanderson
Mar 13, 1999·Thrombosis Research·J Hauptmann, J Stürzebecher
Jun 27, 2002·Trends in Pharmacological Sciences·Niki Zacharias, Dennis A Dougherty
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·R A GalemmoP F Stouten
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·J M FevigR R Wexler
Mar 4, 2000·Bioorganic & Medicinal Chemistry Letters·Y GongJ Gao
Mar 4, 2000·Bioorganic & Medicinal Chemistry Letters·R A GalemmoR R Wexler
Dec 12, 2001·Bioorganic & Medicinal Chemistry·Jian CuiMichael E Johnson
Sep 16, 1998·Current Opinion in Chemical Biology·A S Ripka, D H Rich
Jul 5, 2005·Expert Opinion on Investigational Drugs·U Sinha
Jul 3, 2013·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·P P ZhangK Li
Apr 10, 2007·Journal of Molecular Graphics & Modelling·H H LinY Z Chen
Dec 8, 2009·Medicinal Research Reviews·Yu-Kai Lee, Mark R Player
Sep 28, 2004·Journal of Chemical Information and Computer Sciences·G MlinsekT Solmajer
Mar 11, 2008·Organic & Biomolecular Chemistry·Masaharu UnoHiroyuki Nakamura
May 17, 2000·Journal of Cardiovascular Pharmacology·D R AbendscheinD R Light
Oct 3, 2012·Journal of Biomolecular Structure & Dynamics·Xian-Li FengXu-Ri Huang
Jul 30, 1999·Journal of Medicinal Chemistry·M L QuanR R Wexler
Jul 30, 1999·Journal of Medicinal Chemistry·M L QuanR R Wexler
Oct 23, 1998·Journal of Medicinal Chemistry·B GabrielL Moroder
Aug 24, 2000·Journal of Medicinal Chemistry·M A KastenholzT Fox
Mar 15, 2000·Journal of Medicinal Chemistry·D K HerronG F Smith
Apr 19, 2007·Journal of Medicinal Chemistry·Donald A PatrickRichard R Tidwell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.